NRG Therapeutics vs PhaseV
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised £50M ($67M) oversubscribed Series B (Sep 2025). First participants dosed in Phase 1 of NRG5051 (Jan 2026). Phase 1 readout expected end of 2026. Oral small molecules targeting mPTP in ALS and Parkinson's.
About
NRG Therapeutics develops first-in-class oral small molecules targeting the mitochondrial permeability transition pore (mPTP) — a protein complex whose aberrant opening triggers the cellular energy failure and neurodegeneration that underlies ALS (amyotrophic lateral sclerosis) and Parkinson's disease. The company raised £50 million ($67 million) in an oversubscribed Series B in September 2025, and dosed the first clinical trial participants for NRG5051 in January 2026, with Phase 1 readout expected by end of 2026.
Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollment 40%, duration 40%. 40+ pharma sponsors. 7 of world's top pharma companies as partners.
About
PhaseV is an AI clinical trial platform that uses predictive analytics to optimize trial design, site selection, patient enrollment, and protocol adherence — delivering dramatic efficiency improvements over traditional trial execution. The company raised $50 million in Series A financing in May 2025 co-led by Accel and Insight Partners, and entered 2026 with 40+ global pharmaceutical sponsors as customers including 7 of the world's top pharmaceutical companies.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.